# Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma

> **NCT02876003** · PHASE2 · WITHDRAWN · sponsor: **GenSpera, Inc.**

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** G-202

## Key facts

- **NCT ID:** NCT02876003
- **Lead sponsor:** GenSpera, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09
- **Primary completion:** 2019-10
- **Final completion:** 2020-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study has been withdrawn prior to enrollment.
- **Last updated:** 2017-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876003, "Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02876003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*